COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults London, UK – 9 May 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today...

COMPASS Pathways and partners launch The Centre for Mental Health Research and Innovation, in the UK Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022  COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”),...

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder London, UK – 3 November 2021             COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...

COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK London, UK – 5 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...